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Objectives: Metastatic melanoma is a rare, but aggressive disease that accounts 
for 90% of deaths related to skin cancer. The objective of this project was to 
estimate average direct medical costs associated with treatment of metastatic 
melanoma in a population of Swiss, adult patients from a third-party payer per-
spective. MethOds: Direct medical costs of drugs and services were estimated 
for the following components: Pharmacotherapy; physician visits; inpatient stays; 
outpatient visits; laboratory tests; imaging and other procedures. Unit costs were 
based on 2015 list prices in Swiss Francs (CHF) and derived from the Swiss offi-
cial tariff schedule (TARMED) for outpatient-related costs, Swiss diagnosis-related 
group (DRG) tariffs for inpatient-related costs, the Swiss Federal Office of Public 
Health for laboratory tests and the Swiss drug Compendium for prescription drugs. 
Estimated average cost per patient was population-weighted and reported for 
three mutually-exclusive designed health states: Pre-progression, progression 
and post-progression. Estimates of the utilization of services and the units of 
service received were based on published literature and a survey of Swiss physi-
cians treating melanoma. Results: For pharmacotherapy, the estimated cost 
for a full treatment course was 79’986.09 CHF for ipilimumab, 104’311.59 CHF for 
vemurafenib, and 1’329.89 CHF for dacarbazine. For parenteral drugs the cost of 
administration for a full treatment course was 1’408.73 CHF for ipilimumab and 
2’077.22 CHF for dacarbazine. Average monthly cost for neurosurgery was 1’101.03 
CHF during progression. Outpatient visits accumulated an average per month 
of 27.40 CHF during pre-progression, 92.40 CHF during progression and 170.23 
CHF during post-progression. Other melanoma-related costs (laboratory tests and 
scans) comprised on average 140.70 CHF per month during pre-progression and 
1’182.37 CHF per month during progression. cOnclusiOns: Based on list prices, 
direct medical costs associated with metastatic melanoma treatment were esti-
mated and reported for patients in an adult, Swiss population.
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Objectives: VTE (venous thromboembolism) are among the frequently associated 
with malignant disease events which requires hospitalization and could generate 
extra costs for the health insurance. There is no French studies analyzing the addi-
tional costs induced by VTE and cancer. The objective of this study is to provide an 
estimation of the additional cost induced by VTE + cancer from the analysis of hos-
pital stays extracted from PMSI 2013 (French Hospital Database) for 4 types of cancer 
(breast, lung, hepatocellular carcinoma and colon). MethOds: A crossed approach 
of Principal Diagnosis (DP) and Comorbidities (DAS) was performed to identify all 
stays combining VTE and cancer. The analysis is divided into 3 parts: a descriptive 
approach of hospital stays for VTE + cancer, an analysis by severity level of DRG and 
an economic valorization based on the National Cost Scale. It was not achieved PMSI 
extraction to create a comparison population for each type of cancer because the 
creation of such a population could be a mood point, in particular because of other 
comorbidities may also generated additional costs (eg infection). Public ATIH database 
was used. The essential approach of this study is based on analysis of the distribution 
of stays according to levels of severity DRG. Results: 14,251 stays were analyzed 
combining VTE and cancer. Stays for VTE + cancer represented 81.7% in the severity 
levels 3 and 4. For example, the average cost of lung cancer in cancer patients+ VTE 
(PMSI extraction) is € 7,296 against € 4,647 for this cancer in ATIH database. A multiply-
ing factor is estimated: 1.57 in lung cancer, 1.5 for breast cancer, 1.34 in colon cancer 
and 2.01 for hepatocellular carcinoma. cOnclusiOns: The economic justification 
for the use of preventive treatment of VTE is here in line with clinical guidelines.
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Objectives: Hepatocellular carcinoma (HCC) is the fifth most common malig-
nancy worldwide imposing high hospitalizations and mortality rates and a 
relevant economic burden. Objective of the present analysis is to investigate treat-
ment pathways and healthcare costs for intermediate and advanced HCC patients 
(Barcelona Clinic Liver Cancer Classification (BCLC) stage B and C). MethOds: 
Structured interviews with gastroenterologists and interventional radiolo-
gists were performed in four Italian centres experienced in HCC management. 
Information on disease stage, diagnostic procedures, treatments and healthcare 
resource consumption related to HCC were recorded. Direct healthcare costs 
associated with relevant treatments (sorafenib, Transarterial chemoembolization 
(TACE), transarterial radioembolization (TARE) systemic treatment) were evalu-
ated. Results: Between 2013 and 2014, 285 patients with HCC (mean age 66 years, 
74% males) were treated in the 4 participating centres; of them, 80 were classified 
in the intermediate stage and 57 in the advanced stage. TACE was the most fre-
quent first-line treatment in intermediate stage HCC (63%), followed by sorafenib 
(15%), radiofrequency ablation (14%) and TARE (1,3%). In the advanced stage of HCC 
the most frequently used first-line therapy was sorafenib (56%), followed by best 
therapy. MethOds: Medical records of 220 patients with metastatic SCCHN who 
received ≥ 3 lines of systemic therapy were abstracted. Clinical and demographic 
information at metastatic diagnosis as well as treatment and supportive care data 
were collected for patients ≥ 18 years initiating third-line systemic therapy between 
1 January 2011 and 30 August 2014. Performance status (PS) was recorded prior to 
each line of therapy. SCCHN-related HCRU was captured until death or last medical 
record. All analyses were descriptive. Results: Most patients were Caucasian (90%), 
male (74%), current or former smokers (85%), with an initial SCCHN diagnosis of 
stage IVC (52%). Median age at metastatic diagnosis was 60 years and most patients 
had an Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 (208/217= 96%). 
For patients with PS= 0/1, the most common first-line treatment was cisplatin+5-
FU (98/208= 47%); docetaxel was the most common second-line (85/177= 48%) and 
third-line treatment (30/117= 26%). For patients with PS≥ 2, the most common first-, 
second-, and third-line treatments were carboplatin+5FU (5/9= 56%), cetuximab 
(12/38= 32%), and methotrexate (21/95= 22%), respectively. Four patients (2%) received 
4 therapy lines while no patient received ≥ 5 lines. Seven patients (3%) received 
radiation and/or surgery for metastatic disease. Most patients received supportive 
care during therapy (85%) and after its discontinuation (89%). SCCHN-related hos-
pitalizations and emergency department visits were reported for 27% and 20% of 
patients during therapy, respectively (vs. 10% and 16% after therapy discontinua-
tion). Median survival after metastatic diagnosis was 25.6 months. cOnclusiOns: 
Patterns of care and HCRU varied among patients with repeatedly treated metastatic 
SCCHN; specific systemic therapies varied by PS. Factors associated with HCRU will 
be examined in future multivariate analyses.
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Objectives: This study aims to evaluate the clinical, medication and economic 
outcome among advanced CRC patients who were relapsed to metastasis in Taiwan 
using reimbursement and cancer registry databases. MethOds: The outcome data 
was form 2 million sampling reimbursement data base of Taiwan’s National Health 
Insurance Research Database (NHIRD) and diseased stage was derived from the 
Taiwan Cancer Registry (TCR) between 2007 and 2011. Diseased stage diagnosed 
for the first time ever of CRC patients was recorded in TCR. Merged database was 
provided by Health and Welfare Statistics Application Center (HWSAC), Ministry of 
Health and Welfare, Taiwan. Metastasis relapse of the advanced CRC patients was 
identified if the patients were prescribed the approved target therapies, i.e. Avastin 
or Erbitux. Descriptive statistics were derived and summarized; Cox regression was 
used to estimate the difference of the relapse proportion and mortality. Results: 
After eliminating the other previous cancer coded in the database, and non- 
reported diseased stages in the merged database. 2,477 patients were derived and 
enrolled into the analysis. Relapse rates were 5.8% and 19.2% among stage III and 
IV CRC patients with median relapse days of 590 and 437. Mortality rates were 21.9 
% and 64.6% with median survival days of 765 and 652. Comparison of the relapse 
rates among different stages was statistical significant with p < 0.0001. Overall costs 
were estimated as an average of 103,616 and 162,714 USD per person during the first 
year since diagnose. cOnclusiOns: Relapse to metastasis stage and mortality rate 
in advanced CRC are still high and estimated medical expenditure increased 57% 
between stage 3 and stage 4 and is possibly due to the high metastatsis relapse rate.
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Objectives: To map the current treatment pathway and resource use in advanced/
metastatic ALK+ non-small cell lung cancer (NSCLC) in Greece, and estimate the 
impact of adding ceritinib in the future treatment pathway. MethOds: An expert 
panel of 7 leading oncologists was convened in order to map the local treatment 
pathway and resource use for ALK+ NSCLC. Published sources provided unit costs 
from the perspective of the Social Insurance Fund (SIF). Direct medical costs were 
included in the analysis: pharmaceutical, medical and hospital care, lab and imaging 
tests, accompanying treatment, and management of AEs and brain metastases for all 
four lines of treatment. Cost base year was 2014. The analysis estimated treatment 
duration based on progression free survival (PFS) from published literature and con-
trolled for estimated brain metastasis frequency by treatment. Results: The current 
treatment pathway in Greece for the management of ALK+ NSCLC utilizes 1st line 
chemotherapy followed by crizotinib, chemotherapy, and palliative care in 2nd, 3rd 
and 4th lines of treatment, respectively. The most widely used 1st line chemothera-
peutic regimen is carboplatin or cisplatin plus pemetrexed (73% of patients); the most 
commonly used 3rd line chemotherapeutic agent is docetaxel (83% of patients). The 
average per patient cost in the current treatment pathway was estimated at € 67,672, 
based on a 20-month treatment duration adjusted for median PFS. The costs associ-
ated with future scenario 1 (crizotinib, ceritinib, chemotherapy, palliative care -treat-
ment duration adjusted to 26 months) and future scenario 2 (chemotherapy, ceritinib, 
chemotherapy, palliative care –treatment duration adjusted to 29.3 months) were 
€ 93,113 and € 105,609, respectively. All cost estimates assumed completion of all four 
lines of treatment and all treatment cycles in each line. cOnclusiOns: Ceritinib in 
the 2nd line treatment of ALK+ NSCLC leads to an increase in total health care costs 
due to improved survival which produces longer treatment duration.
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costs are not yet clear. Purpose of this project is to explain from the economic point 
of view about the future urologic surgery. MethOds: In order to analyse the lapa-
rotomy and robotics techniques, we approached costs and revenues. The formers 
are standardized for each kind of surgery, starting from a common case study led by 
the two hospitals of Modena. The latter are extracted punctually from the internal 
database. Finally we focused on the benefits and complications for the patients 
for the two kinds of techniques. Results: In 2014 the hospitals have provided 91 
robotic surgeries and 25 in open-surgery. Revenues for robotic activities are about 
623.539€ while those for open-surgery are 162.045€ , with an average value for each 
patient respectively of 6.852€ (A) and 6.481€ (B). The average hospitalization for 
robotic activities is about 6 days, versus the 10 days for the open-surgery. From the 
analysis above, the costs of robotics are about 6.000€ (D), while the open-surgery 
2.000€ (E). Average income of robotics (A), standardized to average hospitality (from 
6 to 10 days), gives an amount of 11.420 € (C). Comparing (C) with (B), the 4.000€ of 
marginality equals the gap between (D) and (E). cOnclusiOns: The results show 
no economic differences between the two techniques. However, according to clini-
cal point of view, the strong clinical benefits of robotics are evident. As explicated 
by the literature, the accuracy of robotics technique, combined with a more rapid 
learning curve, guarantee a more rapid recovery of urinary tract functionality. 
Despite the goodness, the simulated analysis embeds limits: there is no warranty 
of transferability.
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Objectives: Recent studies suggest that Androgen-Deprivation-Therapy is associ-
ated with increased risk for patients with hormone-sensitive prostate cancer (PCa) 
and pre-existing cardiovascular (CV) disease. Hereunder, the slightly more expensive 
GnRH-antagonist shows a beneficial risk profile over GnRH-agonists. Therefore the 
objective of the present study was to assess the cost-effectiveness of degarelix com-
pared to GnRH-agonists for PCa-patients with pre-existing CV disease. MethOds: 
This analysis is based on a pooled analysis of six Phase III-RCTs comparing GnRH-
agonists with degarelix addressing CV-events in PCa-patients (Albertsen et al.2014). 
For the combined endpoint of CV-events or death a superiority of degarelix was 
determined with a Number-Needed-to-Treat (NNT) of 12. From German sick funds 
perspective, this study estimates and validates the additional degarelix drug costs 
to the cost of one (avoided) CV-event. The CV-event costs were estimated via emer-
gency treatment, inpatient hospital treatment and rehabilitation. The difference of 
these two cost pools divided by 12 (patients) yields the average saving per patient 
and year. To validate the robustness of results, sensitivity analyses were performed 
for choice of comparator, variations in the NNT (number of included studies and 
study length) and real world cost data. Results: Compared to the most commonly 
prescribed GnRH-agonist (Trenantone) additional drug costs for degarelix amount 
to € 3,111 for the treatment of 12 PCa-patients. For the prevention of one CV-event 
average savings of € 8,297 are generated. Hence, average savings of € 432/year/patient 
are generated. While examining only studies with CV-events (NNT= 11) or when 
assuming the same length of all studies (NNT= 13) savings amount to € 495 and 
€ 379, respectively. Switching to compare to the cheapest comparator or taking into 
account CV-event real world cost data (€ 9,392 per event) savings of € 62 and € 523 are 
generated, respectively. cOnclusiOns: Degarelix is cost-effective for PCa-patients 
with increased CV-risk compared to GnRH-agonists, also under consideration of 
various sensitivity analyses.
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Objectives: Through the earlier detection and removal of cancerous and precan-
cerous adenomas, colorectal cancer (CRC) screening aims to reduce both the risk 
to individuals and burden on healthcare systems. Inadequate bowel preparation 
prior to colonoscopy correlates with a higher rate of missed adenomas, especially 
in the right colon. The differential cost and efficacy of available bowel cleansing 
products mean that healthcare providers are faced with a decision that has both 
economic and public health consequences. A model was therefore constructed to 
investigate the long term benefits of adequate bowel cleansing. MethOds: The 
cost-consequence model compares the total cost of colonoscopy, and treatment of 
subsequent CRC, over a 10 year time horizon in a cohort of 10,000 patients aged ≥ 55 
years receiving either 4L of polyethylene glycol (4LPEG), 2L of PEG with ascorbate 
(2LPEG+ASC), or 1L of sodium picosulphate with magnesium citrate (NaPic/MgCit) 
prior to colonoscopy. Rates of successful bowel cleansing, completed colonoscopies, 
and adenoma detection rate (ADR) were obtained from clinical trial data, together 
with published rates of surveillance colonoscopy, associated costs, and healthcare 
resource utilisation in Germany. Results: In the model, poor compliance with 
the higher volume 4LPEG leads to a lower rate of completed colonoscopies, and 
more missed adenomas than with lower volume 2LPEG+ASC. Moreover, the superior 
compliance and higher ADR achieved using 2LPEG+ASC, particularly in the right 
colon, results in more cases of CRC prevented over 10 years than 4LPEG and NaPic/
MgCit (25 and 113 more cases, respectively). Through a decrease in treatment of 
CRC, this equates to an average overall cost saving of € 213 and € 625 per patient, 
respectively, over 10 years. cOnclusiOns: Optimisation of bowel cleansing prior 
to colonoscopy is likely to increase the detection (and removal) of cancerous and 
precancerous adenomas, which may reduce the development of CRC, avoid treat-
ment costs, and reduce mortality.
supportive care (21%), TACE (18%) and TARE (3,5%). The mean duration of treat-
ment with sorafenib (a total of 137 patients) was 6.1 months; the average number 
of TACE and TARE sessions was 2.5 and 1.5 procedures/patient, respectively. The 
total costs of treatment per patient amounted to 12,215€ for sorafenib, 13,419€ 
for TACE and 26,106€ for TARE; variability in treatment patterns among centres 
was observed. cOnclusiOns: The present analysis raises for the first time the 
awareness of the overall costs incurred by the Italian National Healthcare Service 
for different treatments used in intermediate and advanced HCC highlighting the 
need for future research and analysis of the cost- effectiveness of TACE alone or 
combined with sorafenib, in the treatment of HCC.
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Objectives: Non-small cell lung cancer (NSCLC) accounts for 85-90% of all lung 
cancers. Anaplastic lymphoma kinase (ALK) gene rearrangement mutations are 
found in 4-7% of NSCLC tumours. Crizotinib is indicated for treatment of patients 
with ALK-positive (ALK+) advanced or metastatic NSCLC. However, patients even-
tually progress/develop resistance over time. There is limited evidence on the 
economic burden among Canadian ALK+ NSCLC patients who discontinue crizo-
tinib. MethOds: A chart review study was conducted to assess treatment patterns, 
resource utilization and associated costs among patients with locally advanced 
or metastatic ALK+ NSCLC, diagnosed 2010-2015, who were intolerant to or pro-
gressed on crizotinib treatment. Data were collected from medical charts from six 
Canadian oncology centres. Cost estimates were calculated using a ‘bottom-up’ 
approach, where frequency of utilization, retrieved by type and frequency, was 
multiplied by each resource unit cost. Costing was performed with the public 
payer’s perspective, and as ceritinib was approved in March 2015, associated costs 
were excluded. Results: A total of 97 charts were included, with 49 crizotinib-
failures, 9 crizotinib-naive and 39 ongoing crizotinib treatment. Among those who 
failed crizotinib treatment, mean age at diagnosis was 53 years, with 53% female, 
53% Caucasian, and 67% non-smokers. Treatment patterns post crizotinib in any 
line of treatment was ceritinib (43%), targeted therapy (6%), platinum doublets 
(23%), single agent chemotherapy (23%)and no further systemic treatment (41%); 
35% and 33% of patients received concurrent palliative care and/or radiotherapy, 
respectively. Median overall survival in patients who received non-ceritinib treat-
ment was 1.7 months. Total mean cost for completed systemic treatment post-
crizotinib was $16,473/patient, excluding ceritinib costs. Other costs included 
palliative care and radiotherapy. Mean monthly cost for resource use was $4,382/
patient. cOnclusiOns: Treatment patterns post-crizotinib were heterogeneous. 
Estimated economic burden in patients who received active treatment remains 
significant despite their poor prognosis.
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Objectives: To analyse chemotherapeutic treatment duration, resource use 
and cost per treatment line in metastatic breast cancer (MBC) patients in the 
Netherlands. To analyse lifetime chemotherapy cost and which patient and disease 
characteristics influence it. MethOds: A database containing information on 
treatment, disease and patient characteristics of 815 MBC patients was analysed. 
Inclusion criteria were: having a confirmed MBC diagnosis and having received 
at least one chemotherapy administration after MBC diagnosis. On and off treat-
ment duration, number of administrations and mean cost were aggregated for 
each regimen in each treatment line. Chemotherapy costs of each regimen in 
each line were corrected for censoring through the Lin’s method. Corrected costs 
were used to calculate treatment line costs and lifetime cost. A generalised linear 
model was used to assess the influence of patient and disease characteristics on 
lifetime chemotherapy cost. Results: Total chemotherapy line durations and 
off treatment durations were highly variable and decreased across treatment 
lines. Taxane-based chemotherapies (docetaxel and paclitaxel) were the most 
often used regimens in the first two lines of treatment. Afterwards, capecitabine, 
vinorelbine and gemcitabine were more often used. The fifth treatment line was 
the most expensive (mean: € 9,501, range: € 555 - € 31,864), followed by the first line 
(mean: € 4,454, range: € 381 - € 47,872). Mean lifetime costs was € 7,360 (range: € 381 - 
€ 73,512) and was significantly influenced by age and metastatic sites at metastatic 
diagnosis. cOnclusiOns: There is a high variability in chemotherapy treatment 
duration, resource use and cost between and within treatment lines. Lifetime 
chemotherapy cost was influenced by metastatic sites and age at metastatic diag-
nosis. Patient and disease characteristics and treatment line number are therefore 
important when determining the cost of chemotherapy for MBC. Consequently, 
(model-based) economic evaluations should incorporate more detailed cost esti-
mates concerning chemotherapeutic treatment for MBC.
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Objectives: Among the therapeutic practices for prostate cancer, open-surgery 
is the most frequent technique. Recent studies have shown that robotics allows 
a recovery of the function more rapid than the classic open-surgery, although the 
